Mehmet Hilmi Dogu
University of Health Sciences Antigua
57 Papers
45 Citations
Mehmet Hilmi Dogu is an academic researcher from University of Health Sciences Antigua. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 5, co-authored 44 publications.
Chat about Author
Papers
Brentuximab vedotin consolidation therapy after autologous stem-cell transplantation in patients with high-risk Hodgkin lymphoma: Multicenter retrospective study
Olga Meltem Akay,Murat Ozbalak,Mustafa Pehlivan,Birol Yildiz,Ant Uzay,Tuğçe Nur Yiğenoğlu,Tugrul Elverdi,Leylagül Kaynar,Orhan Ayyildiz,İpek Yönal Hindilerden,Hasan Sami Goksoy,Sebnem Izmir Guner,Ahmet Kursad Gunes,Mehmet Sönmez,Meltem Kurt Yuksel,Sinem Civriz Bozdag,Zübeyde Nur Özkurt,Tayfur Toptas,Mehmet Hilmi Dogu,Ozan Salim,Güray Saydam,Irfan Yavasoglu,Meltem Ayli,Gülsüm Özet,Murat Albayrak,Elif Birtas Atesoglu,Selami Kocak Toprak,Rahsan Yildirim,Özgür Mehtap,Sevgi Kalayoglu Besisik,Meliha Nalcaci,Fevzi Altuntaş,Burhan Ferhanoglu +32 more
TL;DR: The AETHERA trial reported an increased progression-free survival (PFS) when brentuximab vedotin (BV) was used as maintenance therapy in high-risk Hodgkin lymphoma (HL) after autologous stem cell transplantation (ASCT).
12
Covid-19 Clinical Course and Blood Groups: Turkish Population-Based Study.
Mehmet Sinan Dal,Naim Ata,Fevzi Altuntaş,Semih Başcı,Tuğçe Nur Yiğenoğlu,Serdal Korkmaz,Sinem Namdaroglu,Abdulkadir Basturk,Tuba Hacibekiroglu,Mehmet Hilmi Dogu,Ilhami Berber,Kursat Dal,Mehmet Ali Erkurt,Burhan Turgut,Murat Caglayan,Ersan Imrat,Osman Celik,Mustafa Mahir Ulgu,Suayip Birinci +18 more
TL;DR: In this paper, the authors investigated the relationship between blood groups and the course of COVID-19 in Turkey and revealed that ABO and Rh blood groups do not have any impact on the rate of hospital admission, hospital and ICU stay, MV support, and case fatality rate (CFR).
11
A Real-life Turkish Experience of Venetoclax Treatment in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia.
Aliihsan Gemici,Fahir Özkalemkaş,Mehmet Hilmi Dogu,Atakan Tekinalp,Inci Alacacioglu,Tekin Guney,Idris Ince,Ayfer Gedük,Gulsum Akgun Cagliyan,Senem Maral,Istemi Serin,Eren Gunduz,Volkan Karakuş,Huseyin Saffet Bekoz,Rafet Eren,İbrahim Ethem Pinar,Ahmet Kursad Gunes,Fatma Deniz Sargın,Ömür Gökmen Sevindik +18 more
TL;DR: The real-life data support the use of venetoclax in patients with both newly diagnosed and relapsed high-risk MDS and AML, and fatigue, diarrhea, and skin reactions were the others reported.
10
Evaluation of neutrophil-lymphocyte ratio in patients with early-stage mycosis fungoides.
TL;DR: It seems that there is no association between the NLR and treatment demand, time to treatment, progression in stage, and time to progression in stages in mycosis fungoides patients.
9
T-cell acute lymphoblastic leukemia with co-expression of CD56, CD34, CD117 and CD33: A case with poor prognosis
TL;DR: This is the first report of aberrant co-expression of the natural killer cell marker CD56, myeloid cell markers CD117 and CD33 and stem cell markerCD34 in a patient with T-cell ALL, which appears to be associated with an unfavorable outcome, despite the use of intensive chemotherapy.